Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 6/20 | 0.64 |
| ▸ | GSK3A | P49840 | 5/20 | 0.64 |
| ▸ | AURKA | O14965 | 3/20 | 0.64 |
| ▸ | PLK1 | P53350 | 3/20 | 0.57 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408359 | 0.88 | MAPT (0.86) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5419368 | 0.85 | GSK3B (0.63) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5522602 | 0.84 | GSK3B (0.57) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5402419 | 0.84 | MAPT (0.62) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5408180 | 0.84 | STK17A (0.66) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5408207 | 0.84 | GSK3B (0.61) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5405521 | 0.84 | GSK3B (0.61) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5402268 | 0.83 | GSK3B (0.82) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5409960 | 0.82 | MEN1 (0.60) | MEN1KMT2AMAPTCYP1A2CYP3A4 | |
| SCHEMBL5407955 | 0.81 | GSK3B (0.59) | MEN1KMT2AMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | MEN1 3119/4885KMT2A 4026/4885MAPT 13/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | MEN1 2729/4885KMT2A 4480/4885MAPT 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.